MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2019 International Congress

    Trends in first line therapy for PD in Wales: A 16 year observational study

    K. Orayj, A. Lacey, A. Akbari, O. Pickrell, E. Lane (Cardiff, United Kingdom)

    Objective: To examine the changes in first line therapy of newly diagnosed Parkinson’s patients between 2000 and 2016 in Wales. Background: There have been several…
  • 2018 International Congress

    Lottery choice task as a detect tool for PD patients with pathological gambling

    W. Liu, R. Wu, J. Goh (Hualien, Taiwan)

    Objective: We aim to develop a tool lack of stigma to detect patients' impulse control problems. Background: Dopaminergic medication is current major treatment for Parkinson's…
  • 2018 International Congress

    Validation of a One-Page Impulse Control Disorder Questionnaire in a Parkinson’s Disease Clinic

    L. Williams, B. Magennis, N. Feerick, T. Lynch (Dublin, Ireland)

    Objective: We seek to report data on ICD symptoms collected on 120 patients with Parkinsonism attending specialist movement disorder outpatient clinics using a newly devised,…
  • 2018 International Congress

    Rotigotine protects dopaminergic neurons by targeting serotonin 1A receptors on astrocytes

    M. Asanuma, I. Miyazaki, N. Isooka, R. Kikuoka, K. Wada, E. Nakayama, K. Shin, D. Yamamoto, Y. Kitamura (Okayama, Japan)

    Objective: In this study, we examined neuroprotective effects of rotigotine and involvement of serotonin 1A (5-HT1A) receptors on astrocytes in neuroprotective action of the drug…
  • 2018 International Congress

    Dissociate effect of dopaminergic therapy in reward expectation and prediction error in PD patients with comorbid impulse control disorder

    JF. Martin-Rodriguez, A. Rodriguez-Baena, L. Garrote Espina, P. Alvarez Toledo, S. Jesus, C. Mendez Barrio, A. Adarmes Gomez, F. Carrillo Garcia, M. Carballo Cordero, P. Mir (Seville, Spain)

    Objective: To study EEG oscillatory activity associated to reward prediction error in Parkinson’s disease (PD) patients with impulse control disorders (ICD) and determine how dopaminergic…
  • 2018 International Congress

    Emulating the natural timing of dopamine receptor activation in Parkinson’s Disease

    J. Reynolds, B. Hyland, J. Wickens, E. Tan (Dunedin, New Zealand)

    Objective: To emulate physiological dopamine receptor activation, in order to restore temporal patterns of dopamine-like signalling and normalise function in the striatum in Parkinson's disease.…
  • 2018 International Congress

    GASTROPARK: Multicenter study on the efficacy of dopamine agonists for gastrointestinal symptoms in Parkinson’s disease

    J. Martinez Castrillo, A. Alonso Canovas, G. Fernandez Pajarin, L. Vela Desojo, J. Garcia Caldentey, P. Sanchez Alonso, M. Fernandez Moreno, M. Mata, J. Herreros Rodriguez, J. Infante, J. Ruiz Martinez, C. Ruiz Huete, S. Fanjul Arbos, P. Garcia Ruiz (Madrid, Spain)

    Objective: Main: To assess the modification of gastrointestinal symptoms in patients with Parkinson's disease before and after the introduction of dopamine agonists. Secondary: (1) To…
  • 2018 International Congress

    Effectiveness of Rotigotine plus Intensive and Goal-based Rehabilitation versus Rotigotine alone in “de-novo” Parkinsonian subjects: A Randomized Controlled Trial with 18-month Follow-up

    D. Ferrazzoli, P. Ortelli, G. Riboldazzi, R. Maestri, G. Frazzitta (Gravedona ed Uniti, Italy)

    Objective: To evaluate the synergism between Dopamine Replacement Therapy (DRT) and rehabilitation in treating Parkinson's disease (PD), by investigating the short and the long-term effectiveness…
  • 2018 International Congress

    On Converting Patients From Oral Dopamine Agonists to the Carbidopa/Levodopa Enteral Suspension Method – Real World Conversion Ratios

    S. Nakano, L. Bahroo, F. Pagan, F. Amjad, S. Lo, I. Gambhir (Washington, D.C., DC, USA)

    Objective: To review guidelines for initiating Carbidopa/Levodopa Enteral Suspension method of delivery in the treatment of Parkinson’s Disease (PD) and to compare guidelines with real…
  • 2018 International Congress

    Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease

    J. Chen, J. Hong, L. Chunfeng (Suzhou, China)

    Objective: We evaluated the efficacy of different starting drugs in the treatment of Parkinson's disease (PD), in order to further explore the initial therapy of…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29077 (not found)
  • #29056 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28189 (not found)
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley